“we've not experienced any impact to our LEN for PrEP filing or any of our clinical trials actually to date. Right? And we continue to expect the lenacapavir decision by June 19.”

In context

“Gilead Sciences, Inc. has been incredibly focused on making sure we continue to have market development initiatives to ensure screening, diagnosis for treatment, but also to ensure awareness within the PrEP market and make sure there's education there as well. I think you've seen that as you think about the PrEP market growth, we had a lot of activities in Q4 of last year, and that's kind of playing out. We saw a nice uplift of the growth of the PrEP market in Q4, and you kind of see that come through again in Q1. At about 16% year over year. So really well positioned as you think about lenacapavir around the corner. Dietmar Berger: Yeah. And then on the FDA side, at this time, you know, all our interactions with the FDA have been on track, have been as expected without any surprises, so we've not experienced any impact to our LEN for PrEP filing or any of our clinical trials actually to date. Right? And we continue to expect the lenacapavir decision by June 19. Our next question comes from James Shin at Deutsche Bank. Rebecca: James, go ahead. Your line is open. James Shin: Thank you. I have a question for Johanna. James Shin: Johanna, the strength in this COVID for this quarter, is there any read-through or implications on it looks like there were some price benefits to Descovy. But is there any read-through or implications to LEN's launch? Johanna Mercier: Yeah. There is. For the question. So, yeah, we saw a really nice growth year on year about 38% growth for Descovy. That was driven by higher average realized price, as you mentioned, as well as higher demand. Those are the two big drivers there's a couple of reasons behind that. One is definitely the PrEP market growth that I was referring to earlier, around 16% year on year, driven really b”